Fmr LLC Summit Therapeutics Inc. Transaction History

Fmr LLC

$1.68 Trillion
Q2 2025

A detailed history of Fmr LLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Fmr LLC holds 9,226,376 shares of SMMT stock, worth $201 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

9,226,376

Previous 9,338,223 1.2%

Holding current value

$201 Million

Previous $180 Million 8.99%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$16.64 - $36.7 $1.86 Million - $4.1 Million	-111,847 Reduced 1.2%	9,226,376 $196 Million
Q1 2025 May 12, 2025	BUY	$16.65 - $23.76 $21.4 Million - $30.5 Million	1,282,853 Added 15.93%	9,338,223 $180 Million
Q4 2024 Feb 13, 2025	SELL	$17.52 - $23.46 $4.34 Million - $5.81 Million	-247,749 Reduced 2.98%	8,055,370 $144 Million
Q3 2024 Nov 13, 2024	BUY	$6.89 - $31.93 $5.08 Million - $23.6 Million	737,692 Added 9.75%	8,303,119 $182 Million
Q2 2024 Aug 13, 2024	SELL	$2.39 - $10.92 $977,758 - $4.47 Million	-409,104 Reduced 5.13%	7,565,427 $59 Million
Q1 2024 May 13, 2024	BUY	$2.55 - $5.07 $20.3 Million - $40.4 Million	7,965,209 Added 85445.28%	7,974,531 $33 Million
Q4 2023 Feb 13, 2024	BUY	$1.67 - $2.83 $10,409 - $17,639	6,233 Added 201.78%	9,322 $24,000
Q3 2023 Nov 13, 2023	BUY	$1.54 - $2.42 $3,794 - $5,962	2,464 Added 394.24%	3,089 $5,000
Q2 2023 Aug 11, 2023	BUY	$1.32 - $2.81 $825 - $1,756	625 New	625 $1,000
Q2 2022 Aug 12, 2022	SELL	$0.92 - $2.38 $670 - $1,735	-729 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$2.0 - $3.45 $1,458 - $2,515	729 New	729 $2,000

Others Institutions Holding SMMT

# of Institutions

264

Shares Held

90.4M

Call Options Held

4.71M

Put Options Held

3.17M

View Full List

About Summit Therapeutics Inc.

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $4.38B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

More about SMMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account